title: Advanced Hodgkin disease (clinical stages IIIB and IV): low relapse rate after brief chemotherapy followed by high-dose total lymphoid irradiation.
abstract: From January 1980 to September 1986, 50 patients with Hodgkin disease, clinical stages (CS) IIIB (26 cases) and IVB (24 cases) were treated by three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy, followed by high-dose (40 Gy) (sub)total lymphoid irradiation, including the spleen. Ten patients (2 CS IIIB, 8 CS IVB) were in failure, and seven (4 CS IIIB, 3 CS IVB) died during their first complete remission (2 from treatment-related complications, 1 from unknown cause, 4 from insufficient supportive care and/or a shortage of health supplies); three patients (CS IIIB) relapsed (2 alive in second complete remission, 1 deceased). After 7 years, actuarial survival and relapse-free duration were, respectively, 64% for the 50 patients and 89% for the 40 patients in complete remission. Unfavourable outcome was observed in patients with pelvic nodal involvement. The low relapse rate (none in CS IVB) was the most striking result after brief chemotherapy followed by total lymphoid irradiation.
authors.affiliation: Hematology Clinic, Centre P.M. Curie, Mustapha Hospital, Algeria.
authors.forename: P
authors.initials: P
authors.lastname: Colonna
authors.forename: J M
authors.initials: JM
authors.lastname: Andrieu
authors.forename: R
authors.initials: R
authors.lastname: Ghouadni
authors.forename: Z
authors.initials: Z
authors.lastname: Zouaoui-Benhadji
authors.forename: M
authors.initials: M
authors.lastname: Afiane
authors.forename: P
authors.initials: P
authors.lastname: Kubisz
authors.forename: J M
authors.initials: JM
authors.lastname: Tourani
authors.forename: K
authors.initials: K
authors.lastname: Belhadj-Merzoug
authors.forename: C
authors.initials: C
authors.lastname: Krisch
authors.forename: A
authors.initials: A
authors.lastname: Laugier
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000473:pathology / Q000628:therapy*; D006801:Humans; D015182:Lymphatic Irradiation / Q000379:methods; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone